A real-world study of the safety and efficacy of galanthamine hydrobromide in the treatment of cognitive impairment

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400081930

Enrollment

Unknown

Registered

2024-03-15

Start date

2024-03-15

Completion date

Unknown

Last updated

2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive impairment

Interventions

treated group:Use of Galantamine Hydrobromide: Upon enrollment, medication was administered at 5mg bid for 2 weeks or increased to 10mg bid according to medical advice, maintained until 24 weeks of tr

Eligibility

Sex/Gender

All

Age

35 Years to 95 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for cognitive impairment in the 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment; (2) Patients with cognitive impairment assessed by the Mini Mental State Examination (MMSE); (3) No obvious visual or hearing impairment, able to complete psychological measurements; (4) Informed consent to complete the intervention plan.

Exclusion criteria

Exclusion criteria: (1) Those who suffer from other serious mental disorders, mental retardation, or mental disorders caused by the abuse of psychoactive substances; (2) Severe asthma, obstructive pulmonary disease, sinus bradycardia, third degree atrioventricular block, and heart failure grades III-IV. (3) Patients with severe prostate hyperplasia and urinary obstruction.

Design outcomes

Primary

Measure	Time frame
Minimum Mental State Examination;activity of daily living,ADL;	—

Countries

china

Contacts

Public ContactHua Ye

Wenzhou People's Hospital

gcpwzsrmyy@163.com+86 139 6880 0035

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026